Technical Analysis for AVCT - Avacta Group Plc

Grade Last Price % Change Price Change
B 122.50 0.00% 0.00
AVCT closed unchanged on Friday, September 29, 2023, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Earnings Movers Other 0.00%
Inside Day Range Contraction 0.00%
20 DMA Support Bullish 0.00%
200 DMA Support Bullish 0.00%
Earnings Movers Other 0.00%
Multiple of Ten Bullish Other 0.00%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 1 day ago
Possible NR7 1 day ago
Down 2% 2 days ago
Fell Below 200 DMA 2 days ago
1.5x Volume Pace 2 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Avacta Group Plc Description

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.


Sector: Healthcare
Industry: Medical Devices
Keywords: Biotechnology Medicine Tools Science Life Sciences Branches Of Biology Clinic Medical Specialties Oncology Immunology Antibodies Immune System Disorders Assay Aptamer Synthetic Antibody

Is AVCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 187.98
52 Week Low 87.9925
Average Volume 1,321,914
200-Day Moving Average 121.12
50-Day Moving Average 107.59
20-Day Moving Average 117.39
10-Day Moving Average 123.40
Average True Range 7.82
RSI (14) 57.45
ADX 17.98
+DI 24.69
-DI 18.20
Chandelier Exit (Long, 3 ATRs) 112.53
Chandelier Exit (Short, 3 ATRs) 123.52
Upper Bollinger Bands 134.58
Lower Bollinger Band 100.20
Percent B (%b) 0.65
BandWidth 29.28
MACD Line 5.02
MACD Signal Line 5.00
MACD Histogram 0.0207
Fundamentals Value
Market Cap 309.5 Million
Num Shares 253 Million
EPS -11.60
Price-to-Earnings (P/E) Ratio -10.56
Price-to-Sales 31.35
Price-to-Book 4.14
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 127.81
Resistance 3 (R3) 127.57 125.55 126.93
Resistance 2 (R2) 125.55 124.20 125.68 126.63
Resistance 1 (R1) 124.03 123.37 124.27 124.27 126.33
Pivot Point 122.01 122.01 122.14 122.14 122.01
Support 1 (S1) 120.49 120.66 120.73 120.73 118.67
Support 2 (S2) 118.47 119.83 118.60 118.37
Support 3 (S3) 116.95 118.47 118.08
Support 4 (S4) 117.19